Hernearin

Hernearin is a naturally occurring coumarin glycoside found in plants such as Matricaria chamomilla and Herniaria species, where it acts as a bioactive phenolic compound with documented anticancer, anti-inflammatory, and cytoprotective properties. Its primary mechanisms involve modulation of oxidative stress pathways and inhibition of pro-inflammatory mediators at the cellular level.

Origin & History

Herniarin is a methoxy-substituted coumarin derived from plants in the Apiaceae family, such as chamomile. It is typically extracted using organic solvents or steam distillation from the plant's aerial parts or essential oils.

Historical & Cultural Context

No specific historical or traditional medicinal uses for herniarin were found. It is known as a constituent of plants like chamomile, which have traditional applications, though specific uses for herniarin are undocumented.

Health Benefits

• Exhibits anticancer activity, particularly against Panc-1 pancreatic cancer cells, with an IC50 of 83.744 µM (preclinical evidence).
• Provides protective effects against cisplatin-induced genotoxicity in rat models (preclinical evidence).
• Demonstrates anti-inflammatory effects in standardized fractions from Distictis buccinatoria (preclinical evidence).
• Shows potential neuroprotective effects in unspecified models (preclinical evidence).
• May suppress metastasis-related genes like MMP2 in cancer cells (preclinical evidence).

How It Works

Hernearin exerts anticancer activity partly through induction of apoptosis and inhibition of cell proliferation in pancreatic cancer cell lines, with an IC50 of 83.744 µM against Panc-1 cells, likely involving disruption of mitochondrial membrane potential and caspase cascade activation. Its cytoprotective effects against cisplatin-induced genotoxicity are mediated through antioxidant activity, including scavenging of reactive oxygen species (ROS) and potential upregulation of endogenous antioxidant enzymes such as superoxide dismutase (SOD) and catalase. Anti-inflammatory activity is associated with inhibition of cyclooxygenase (COX) enzymes and suppression of NF-κB-driven pro-inflammatory cytokine production, including TNF-α and IL-6.

Scientific Research

There are no human clinical trials or meta-analyses available for herniarin. The evidence is limited to preclinical studies, including in vitro cytotoxicity studies against cancer cell lines and in vivo rat studies on genotoxicity.

Clinical Summary

Current evidence for hernearin is entirely preclinical, derived from in vitro cell culture studies and animal models, with no published human clinical trials as of the current literature. Anticancer activity was demonstrated in Panc-1 pancreatic cancer cell lines with a quantified IC50 of 83.744 µM, indicating moderate cytotoxic potency in a laboratory setting. Genoprotective effects were established in cisplatin-treated rat models, where hernearin reduced markers of DNA damage and oxidative stress compared to untreated controls. Anti-inflammatory properties have been observed in standardized experimental models, though effect sizes and precise dosing from animal studies cannot be directly translated to human recommendations without clinical validation.

Nutritional Profile

Herniarin (7-methoxycoumarin; C₁₀H₈O₃; MW 176.17 g/mol) is a simple coumarin derivative, not a macronutrient or dietary supplement, and therefore does not possess a conventional nutritional profile (no protein, fat, carbohydrate, fiber, vitamin, or mineral content in a dietary sense). Key bioactive characteristics: • It is a methyl ether derivative of umbelliferone (7-hydroxycoumarin), classified within the coumarin family of phenylpropanoids. • Naturally occurring concentrations vary by plant source: found in Chamomilla recutita (German chamomile) essential oil at approximately 0.1–3.0% of essential oil content; present in Herniaria glabra (smooth rupturewort) at trace to low-milligram-per-gram levels in dried herb; also identified in Artemisia, Lavandula, and Distictis buccinatoria species. • Lipophilic character (LogP ~1.89) contributes to moderate membrane permeability; oral bioavailability data in humans is limited, but in vitro and rodent pharmacokinetic studies suggest reasonable gastrointestinal absorption with hepatic Phase I (CYP450-mediated O-demethylation back to umbelliferone) and Phase II (glucuronidation, sulfation) metabolism, likely resulting in moderate systemic bioavailability. • Primary bioactive compounds co-occurring in herniarin-rich plant extracts include umbelliferone, scopoletin, apigenin, luteolin, chamazulene, and α-bisabolol, which may contribute synergistically to observed pharmacological effects. • Reported in vitro IC₅₀ values: ~83.7 µM against Panc-1 pancreatic cancer cells; cytotoxic and antiproliferative activity also noted against select other cancer cell lines at micromolar concentrations. • Anti-inflammatory activity attributed to inhibition of NF-κB signaling and suppression of pro-inflammatory cytokines (TNF-α, IL-6) at concentrations typically in the 10–100 µM range in cell-based assays. • No established Recommended Daily Intake (RDI), Tolerable Upper Intake Level (UL), or recognized dietary reference values exist. Herniarin is studied exclusively as a phytochemical compound with pharmacological potential, not as a nutritional component.

Preparation & Dosage

No clinically studied dosage ranges exist due to the absence of human trials. Preclinical studies use herniarin-loaded solid lipid nanoparticles with IC50 values of 83.744–138.34 µM in cancer cell models. Consult a healthcare provider before starting any new supplement.

Synergy & Pairings

Chamomile, Daphnoretin, Curcumin, Resveratrol, Green tea extract

Safety & Interactions

Hernearin lacks human clinical trial data, making a comprehensive safety profile difficult to establish; however, coumarins as a class are associated with potential hepatotoxicity at high doses and should be used cautiously by individuals with liver conditions. Because coumarin derivatives can exhibit anticoagulant properties, hernearin may theoretically potentiate the effects of blood-thinning medications such as warfarin, increasing bleeding risk, though direct interaction data for hernearin specifically are not established. Pregnant and breastfeeding women should avoid hernearin-containing preparations due to the absence of safety data and known concerns regarding coumarin compounds during pregnancy. Individuals taking cisplatin or other chemotherapy agents should consult an oncologist before use, as preclinical genoprotective interactions could theoretically alter chemotherapy efficacy.